Cargando…

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

BACKGROUND: Neurologic complications as myelitis are very rare but extremely deleterious adverse effects of both immunotherapy and radiotherapy. Many recent studies have focused on the possible synergy of these two treatment modalities due to their potential to enhance each other’s immunomodulatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carausu, Marcela, Beddok, Arnaud, Langer, Adriana, Girard, Nicolas, Bidard, François-Clément, Massiani, Marie-Ange, Ricard, Damien, Cabel, Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868866/ https://www.ncbi.nlm.nih.gov/pubmed/31753021 http://dx.doi.org/10.1186/s40425-019-0803-x

Ejemplares similares

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
por: Porte, Judith, et al.
Publicado: (2022)

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
por: Santi, Daniel V., et al.
Publicado: (2021)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
por: Ikeda, Taro, et al.
Publicado: (2021)

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023)

Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
por: Seban, Romain-David, et al.
Publicado: (2020)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab
por: Charabi, Salma, et al.
Publicado: (2021)

Circulating Tumor Cells in Early Breast Cancer
por: Thery, Laura, et al.
Publicado: (2019)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Myelitis
por: Hay, Walter
Publicado: (1874)

Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centre
por: Thery, Laura, et al.
Publicado: (2021)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Lithium rechallenge after renal transplant
por: Beasley, Anna K., et al.
Publicado: (2018)

5-Fluorouracil Rechallenge After Cardiotoxicity
por: Desai, Aakash, et al.
Publicado: (2020)

Transverse Myelitis
por: Beh, Shin C., et al.
Publicado: (2013)

Myelitis and Meningitis
por: Sorjonen, Donald C.
Publicado: (1992)

Transverse Myelitis
por: Lim, Peter A.C.
Publicado: (2020)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
por: Vasseur, Antoine, et al.
Publicado: (2022)

RECOVERY AND RECHALLENGE AFTER THE NEUROLEPTIC MALIGNANT SYNOROME
por: Chopra, Mohit P., et al.
Publicado: (2001)

Time to rechallenge primary prevention ICD guidelines
por: Wong, Bethany, et al.
Publicado: (2022)

Etanercept-associated myelitis
por: Finke, Carsten, et al.
Publicado: (2015)

Leprous ganglionitis and myelitis
por: Rice, Claire M., et al.
Publicado: (2016)

Myelitis and Pulmonary Tuberculosis
Publicado: (1905)

Case of Idiopathic Myelitis
por: Black, Donald Campbell
Publicado: (1867)

Myelitis of the Anterior Horns
Publicado: (1877)

Constipation in transverse myelitis
por: Chinnappan, Justine, et al.
Publicado: (2023)

Acute Flaccid Myelitis
por: Zappa, Dane, et al.
Publicado: (2022)

Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an Independent Risk Factor for Inpatient Mortality in a Population of Cancer Patients: A Prospective Study
por: Ramtohul, Toulsie, et al.
Publicado: (2020)

Bbibp-corv: Myelitis including longitudinally extensive transverse myelitis: case report
Publicado: (2022)

Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma
por: Takeda, Hiroki, et al.
Publicado: (2021)

Extensive myelitis associated with anti-NMDA receptor antibodies
por: Outteryck, Olivier, et al.
Publicado: (2013)

Dysphonia after Bevacizumab Rechallenge: A Case Report
por: Carter, Corey A., et al.
Publicado: (2015)

Effective long-term temozolomide rechallenge in a macroprolactinoma
por: Zampetti, Benedetta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_boh9v6bliofarlagmj0j081im8